[1]
I. Haznedaroglu, “MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)”, MJHID, vol. 6, no. 1, p. e2014009, Dec. 2013.